Effects of ^superFVa and 4F-PCC on thrombin generation in NHP spiked with FXa inhibitors. Thrombin generation was measured in NHP in the presence of the FXa inhibitors, apixaban or rivaroxaban. (A,D) Representative graphs showing the change in thrombin generation curves as the result of increasing concentrations of 4F-PCC (0-1.35 U/mL) in the presence or absence of ^superFVa (50 nM) in NHP spiked with apixaban (200 nM) (A) or rivaroxaban (200 nM) (D). (B,E) Enhancement of ETP by increasing concentrations of 4F-PCC (0-1.35 U/mL) in the absence (∎) or presence (○) of ^superFVa (50 nM) in NHP spiked with apixaban (200 nM) (B) or rivaroxaban (200 nM) (E). (C,F) Enhancement of ETP by increasing concentrations of ^superFVa (0-50 nM) in the absence (Δ) or presence (○) of 4F-PCC (1.35 U/mL) in NHP spiked with apixaban (200 nM) (C) or rivaroxaban (200 nM) (F). Peak height and lag time of (B-C) are shown in supplemental Figure 5 and of (E-F) in supplemental Figure 6. Additional controls shown are NHP with (□) and without (◇) apixaban or rivaroxaban or NHP with 1.35 U/mL 4F-PCC (∇). Error bars represent standard error of the mean (n ≥ 3).